Table 1.
Clinical characteristics of patients.
| Characteristics of Patients, n = 18 | |
|---|---|
| Age at TKI start, years | |
| Median (range) | 69 (30–96) |
| Mean ± SD | 67.5 ± 13.8 |
| Gender, n (%) | |
| Female | 11 (61) |
| Male | 7 (39) |
| Histology, n (%) | |
| DTC | 8 (44.5) |
| PDTC | 8 (44.5) |
| MTC | 2 (11) |
| Site of metastasis, n (%) | |
| Distant metastasis | 13 (72.3) |
| Local disease | 5 (27.7) |
| Patients with of bone metastasis, n (%) | 6 (33.3) |
| Numbers of anatomical site involved, n (%) | |
| 1 | 5 (27.8) |
| 2 | 4 (22.2) |
| ≥3 | 9 (50) |
| Initial dosage, n (%) | |
| 24 mg | 14 (77.7) |
| 14 mg | 4 (22.3) |
| Lenvatinib line of treatment, n (%) | |
| First | 14 (77.8) |
| Second/third | 2 (22.2) |
| Best response | |
| PD | 1 (5.5) |
| PR | 8 (44.5) |
| SD | 9 (50) |
| Time to reach the best response, months | |
| Median (range) | 7.4 (1.9–21.2) |
| Mean ± SD | 8.8 ± 6 |
| Duration of lenvatinib treatment, months | |
| Median (range) | 25.9 (2.7–52.9) |
| Mean ± SD | 23.0 ± 15.1 |